NORDIC BIOTECH GENERAL PARTNER ApS: Financial statements 2020
CVR: 26270367
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
NORDIC BIOTECH GENERAL PARTNER ApS (CVR 26270367) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -765,000 and a net result of DKK -784,289 compared with DKK 7,490 the year before. Equity in the 2020 report amounted to DKK 921,951. The solvency ratio was 98.1%.
- Gross Profit
- DKK -765,000
- Profit/Loss
- DKK -784,289
- Equity
- DKK 921,951
- Total Assets
- DKK 939,451
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -765K | -784K | 922K | - |
| 2019 | - | 16K | 7K | 1.7M | - |
| 2018 | - | -417K | -421K | 1.7M | 0 |
| 2017 | - | 2.4M | 1.8M | 2.1M | - |
| 2016 | - | 16K | 11K | 281K | - |
Official annual report
How creditworthy is NORDIC BIOTECH GENERAL PARTNER ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
NORDIC BIOTECH GENERAL PARTNER ApS has published its annual report for 2019. Gross profit came to DKK 16,250, and the net result was DKK 7,490.
About NORDIC BIOTECH GENERAL PARTNER ApS
NORDIC BIOTECH GENERAL PARTNER ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2001. The company is in liquidation. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Jakob Mosegaard Larsen. The company is owned by TECH GROWTH INVEST ApS and C. HANSEN INVEST ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 163,699 and a net result of DKK 178,169 compared with DKK 67,346 the year before. Equity in the 2025 report amounted to DKK 1,214,065.